Stem cells, *in vitro* gametogenesis and male fertility

Go Nagamatsu and Katsuhiko Hayashi

*Department of Stem Cell Biology and Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan*

Correspondence should be addressed to K Hayashi; Email: hayashik@hgs.med.kyushu-u.ac.jp

This paper is part of an Anniversary Issue celebrating 25 Years of ICSI. The Guest Editor for this section was Professor Gianpiero Palermo.

Abstract

Reconstitution in culture of biological processes, such as differentiation and organization, is a key challenge in regenerative medicine, and one in which stem cell technology plays a central role. Pluripotent stem cells and spermatogonial stem cells are useful materials for reconstitution of germ cell development *in vitro*, as they are capable of differentiating into gametes. Reconstitution of germ cell development, termed *in vitro* gametogenesis, will provide an experimental platform for a better understanding of germ cell development, as well as an alternative source of gametes for reproduction, with the potential to cure infertility. Since germ cells are the cells for 'the next generation', both the culture system and its products must be carefully evaluated. In this issue, we summarize the progress in *in vitro* gametogenesis, most of which has been made using mouse models, as well as the future challenges in this field.

*Reproduction* (2017) 154 F79–F91

Introduction

Gametes are highly specialized cells for the creation of new individuals. To finally become functional gametes, the germ cell lineage including the precursors undergoes a unique series of differentiation processes orchestrated by genetic and epigenetic regulations (McLaren & Lawson 2005, Sasaki & Matsui 2008). Conceptually, the process can be divided into two phases. In the first phase of differentiation, which is sex independent, the cells propagate as a founder population while erasing epigenetic memories in the genome. In the second phase of differentiation, which is sex dependent, the cells undergo remarkable morphological changes with *de novo* epigenetic modifications while halving the genome by meiosis. The first phase commences in primordial germ cells (PGCs) that are specified at an early stage of embryogenesis (Lawson & Hage 1994, Ohinata et al. 2005). Once PGCs are specified, they erase CpG methylation and begin to reorganize histone modifications at a genome-wide level (Seki et al. 2005). PGCs migrate toward the gonad while proliferating and acquire an ‘epigenetic ground state’ upon settling in the gonad. The cell population is the founder for the subsequently second phase. During the first phase, there is no clear difference in gene expression and differentiation potency between males and females (Adams & McLaren 2002, Jameson et al. 2012). In the second phase, however, differentiation becomes more complicated and interactive with surrounding somatic cells. Once entering the female gonad, PGCs enter meiosis (thereby becoming primary oocytes). At the perinatal stage, a majority of oocytes are eliminated by cell death (Pepling & Spradling 2001, McClellan et al. 2003) and the remaining oocytes form primordial follicles that function as a storage of oocytes, ensuring the longevity of the reproductive life in the female. After puberty begins, some of the primordial follicles periodically undergo follicular development, which is characterized by proliferation of granulosa cells, maturation of theca cells and oocyte growth accompanied with *de novo* epigenetic modifications in the genome. When the oocyte growth reaches the plateau stage, meiosis resumes until it is arrested again at the meiotic metaphase II (MII) stage for fertilization. In the male gonad, on the other hand, PGCs are arrested at the G1 stage, and thereby become prospermatogonia. During the cell cycle arrest, the prospermatogonia acquire *de novo* epigenetic modifications (Davis et al. 2000, Ueda et al. 2000, Ly et al. 2015). After birth, some of the prospermatogonia become spermatogonial stem cells (SSCs), which are crucial for sustaining spermatogenesis. After puberty begins, SSCs become differentiated types of spermatogonia, followed by spermatocytes, in which meiosis takes place to form haploid spermatozoids. By tight interaction with Sertoli cells, mature spermatozoa with tiny heads and long tails are formed from the spermatozoids.
One of the key goals in reproductive biology is to reconstitute all the processes of gametogenesis in culture, in order to produce a functional egg and sperm. Such in vitro gametogenesis will make it easy to analyze the complicated process of germ cell development. This may be particularly effective for the analysis of nascent PGCs, because the number of these cells is quite small in the embryos. In other words, in vitro gametogenesis could replace the use of experimental animals in accordance with the Animal Welfare Acts of various nations. From a more practical point of view, gametes produced by in vitro gametogenesis, termed in vitro gametes, could be an alternative source for animal reproduction, such as for the propagation of endangered animals (Saragusty et al. 2016). Moreover, once the capability for producing human in vitro gametes exists, their great potential utility will necessitate a discussion as to whether they should be used for human reproduction. Due to the unique capability of the germ cell lineage, in vitro gametogenesis has a huge impact on a wide range of research. Recent progress in mice suggests that in vitro gametes are not a fantasy, but realistically achievable materials that will promote basic research and provide a practical strategy for reproduction. These achievements are based on accumulating knowledge on developmental biology, stem cell biology and cell culture technologies. Stem cells in particular are an essential material for realizing in vitro gametogenesis, since they can propagate indefinitely under certain conditions while maintaining their ability to differentiate.

Reconstitution of PGC specification in vitro

Reconstitution of PGC specification is an initial and important step for in vitro gametogenesis. Since PGCs are the founder cell population that undergoes genome-wide reprogramming, their quality would reflect the developmental competence of in vitro gametes. To briefly review PGC specification in vivo in the mouse model, PGCs arise from the proximal part of the pluripotent epiblast in response to bone morphogenetic protein (BMP) 4 secreted from the adjacent extraembryonic ectoderm at around embryonic day (E) 6.5 (Lawson et al. 1999). During specification, a set of transcription factors, such as Blimp1/Prdm1, Prdm14 and Tiap2c, orchestrate a PGC-specific gene expression program accompanied with epigenetic reprogramming represented by a reduction of CpG methylation, di-methylation on histone H3 lysine 9 (H3K9me2) and a gradual increment of tri-methylation of histone H3 lysine 27. A key message of PGC specification in vivo is that unique responsiveness to BMP4, termed PGC competence, is conferred temporarily in the epiblast (Ohinata et al. 2009). This clearly indicates that the pluripotent state of the epiblast is distinct from that of the inner cell mass of the blastocyst that is the origin of ESCs. Therefore, to precisely reconstitute PGC specification in vitro, it is first necessary to confer PGC competence to ESCs.

The pluripotent state is currently subdivided into two phases: the naïve and prime states. The former closely resembles the pre-implantation epiblast of the blastocyst while the latter resembles the post-implantation epiblast around gastrulation (Nichols & Smith 2009). The two states require different sets of growth factors for their self-renewal and are interchangeable under certain culture conditions. In mice, neither of the states has PGC competence (Ying et al. 2003, Hayashi & Surani 2009). Instead, the competence is temporarily conferred during transition from the naïve state to the primed state. When mouse ESCs are cultured with bFGF and activin A, which drive the primed state, PGC-like cells (PGCLCs) can be efficiently induced from cells at 2 days of culture in response to BMP4 (Fig. 1) (Hayashi et al. 2011). The gene expression profile and epigenetic status of PGCLCs are highly similar to those of PGCs in vivo. Importantly, PGCLCs are functional, as they develop into sperm and oocytes in the transplanted testes and ovaries, respectively (Hayashi et al. 2011, 2012). The semi in vitro sperm and oocytes are capable of full-term development. The offspring from the semi in vitro gametes are apparently normal, as they grew up without developmental retardation or premature death.
and then become fertile adults that produce normal-sized litters. These studies demonstrated that culture systems successfully reconstitute the PGC specification process. Indeed, this system has been used to determine a set of transcription factors sufficient for PGC specification and epigenetic reprogramming in nascent PGCs (Nakaki et al. 2013; Kurimoto et al. 2015), underscoring the power of in vitro gametogenesis for improving our understanding of germ cell development.

In humans, reconstitution in vitro of PGC specification has also been reported (Irie et al. 2015; Sasaki et al. 2015). As in the mouse model, the question of how best to confer PGC competence is the key issue (Fig. 1). Irie and coworkers cultured ESCs/iPSCs under a ‘4i’ condition that included inhibitors for GSK3β, MEK, JNK and p38 (Gafni et al. 2013; Irie et al. 2015). Human ESCs/iPSCs cultured under this condition, followed by pre-induction culture with TGFβ1 (or activin A) and bFGF, were capable of differentiating into PGCLCs in response to BMP4, SCF, LIF and EGF, which is the same as the set of cytokines used for mouse PGCLC induction. Eventually, the group found that PGCLCs could be derived directly from ESCs/iPSCs cultured under the 4i condition. At almost the same time, Sasaki and coworkers reported another set of culture conditions that confers PGC competence to human iPSCs: they showed that iPSCs cultured with activin A and a GSK3β inhibitor were transformed into incipient mesodermal cells (iMeLCs). iMeLCs efficiently differentiated into PGCLCs in response to BMP4, SCF, LIF and EGF (Sasaki et al. 2015). Irrespective of which method is used, the resulting PGCLCs have gene expression profiles and epigenetic genome modifications that are similar to those of human PGCs (Kobayashi et al. 2012). SOX17 has a human-specific role on PGCLC specification: enforced expression of SOX17 and PRDM1/BLIMP1 at a similar level is sufficient for PGCLC specification (Kobayashi et al. 2017). This kind of experiment can be done only in an in vitro culture model, especially in humans.

Reconstitution of the female germ line: oogenesis in organ culture systems

Reconstitution of the second phase is more challenging, as the process takes a much longer time than PGC specification and proceeds in a sex-dependent manner that is in part regulated by the surrounding somatic cells. To accomplish the second-phase reconstitution, development of an organ culture system seems prerequisite. For oogenesis, there are milestone studies on organ culture systems that succeeded in the production of mature oocytes from residual precursors (Fig. 2). O’Brien and Eppig developed a two-step culture system that produces fully functional oocytes from neonatal ovaries in culture (Eppig & O’Brien 1996; O’Brien et al. 2003). In their system, the secondary follicles were isolated from neonatal ovaries cultured for 8 days, and the secondary follicles were further cultured for an additional 14 days. Fully grown germinal vesicle (GV) oocytes were then cultured with FSH and EGF to become MII oocytes. It is of particular importance that MII oocytes developed to offspring by in vitro fertilization followed by transplantation to surrogate mothers. This culture scheme provides a prototype of in vitro oogenesis.

Partly in continuation of the prototype, Morohaku and coworkers established an organ culture system that produces mature oocytes using fetal ovaries. Notably, the system produced MII oocytes, followed by fertilized eggs, from mitotic PGCs in the fetal ovaries, thereby for the first time demonstrating the successful completion of meiosis in a female germ line in culture (Fig. 2) (Morohaku et al. 2016). Apart from the completion of meiosis, the culture system provides two important components that are requisite to achieving a robust production of oocytes in culture. The first is the prevention of multi-oocyte follicle (MOF) formation by inhibiting estrogen-mediated signaling. In the organ culture of fetal ovaries, MOFs, which are follicles containing more than two oocytes, are frequently formed, and eventually disturb the oocyte growth in culture. Based on previous reports...
that steroid hormones such as estrogen and progesterone trigger MOF formation (Iguchi et al. 1990, Kezele & Skinner 2003, Lei et al. 2010, Zhang et al. 2012, Dutta et al. 2014), Morohaku and coworkers used an estrogen inhibitor, IC1182780, in their organ culture system. This dramatically prevented MOF formation and improved the yields of secondary follicles. The second crucial component is recapitulation of the follicular environment by using polyvinyl pyrrolidone (PVP). In the organ culture system, the mural follicle walls were removed by treatment with collagenase, and the remainder of the follicle structures including oocytes was cultured in medium containing PVP at 2%, in which oocytes grew efficiently to fully grown GV oocytes. Although the detailed mechanism is unclear, it seems that the polymer material increases the viscosity of the medium, which may prevent diffusion of paracrine molecules (Hirao et al. 2004). This might mimic the follicular environment that is enclosed by granulosa and theca cells. The GV oocytes were then cultured in a medium containing LH and EGF. Importantly, the resultant MII oocytes from the culture were capable of fertilization and full-term development (Morohaku et al. 2016).

Reconstitution of the female germ line: oogenesis from pluripotent stem cells

Combining the technologies of the PGCLC system and the organ culture system, Hikabe and coworkers developed a culture system that produces mature oocytes from mouse ESCs/iPSCs (Fig. 2) (Hikabe et al. 2016). Because PGCLCs are arrested in a premigratory state, they need to be aggregated with somatic cells from female embryos at E12.5. The somatic cells give signal(s) that conduct PGCLCs into oogenesis. In the aggregates, which are termed reconstituted ovaries (rOvaries), the PGCLCs immediately start to express MVH, a late PGC marker gene, and then enter meiosis. In the successful organ culture systems, the rOvaries were cultured under three different conditions—in vitro differentiation (IVDi), in vitro growth (IVG) and in vitro maturation (IVM)—in which oogenesis proceeds to primary oocytes in the secondary follicle, fully grown GV oocytes and MII oocytes, respectively. During IVDi culture, primary oocytes from ESCs/iPSCs proceeded to meiosis prophase I and eventually formed follicular structures.

Much as in the organ culture systems, individual secondary follicles were isolated and then treated with collagenase to expose the inside of the follicle structure to the medium. Under the IVG condition, the granulosa cells proliferated and oocytes simultaneously grew up. Cumulus-oocyte complexes (COCs) were eventually lifted up onto the bottom of the culture device, and exhibited a morphology resembling that of antral follicles. Oocytes in the COCs resumed meiosis and then became MII oocytes with a first polar body in IVM culture. The gene expression dynamics during oocyte differentiation in culture was largely similar to that in vivo. Importantly, ESC/iPSC-derived MII oocytes were capable of fertilization and full-term development. However, pups were produced with 20-fold lower efficiency from ESC-derived eggs than from eggs in vivo, suggesting that the quality of oocytes is at least partly compromised. Further refinement of the culture conditions will be required to improve the quality of oocytes produced in vitro. Nevertheless, since gene modification can be easily done in ESCs/iPSCs, this culture system is expected to accelerate research into gene functions in oogenesis. Moreover, it may prove to be an alternative source of eggs in mice.

Reconstitution of the male germ line: organ culture of the testis to produce mature sperm

There are several fragments of reconstitution of the male germ line. This is due to the more complicated steps in spermatogenesis—which typically include self-renewal of SSCs—compared to the corresponding steps in the female germ line. Partly for this reason, successful production of mature sperm from ESCs/iPSCs in culture has not been achieved in the male germ line as it has in the female one. Instead, a number of partial reconstitutions of spermatogenesis have been reported (Fig. 3).

The development of an organ culture system is the first step in the production of mature sperm in culture. Studies on such an organ culture system have been made for a century (Fig. 3) (Champy 1920). In 1937, Martinovitch cultured newborn testicular tissue on a blood clot and observed the progression to pachytene spermatocytes (Martinovitch 1937). Subsequently, in the 1960s, several research groups made extensive efforts to develop organ culture methods in rodents (Steinberger et al. 1964a,b, Steinberger & Steinberger 1967). However, they were unable to progress spermatogenesis beyond the pachytene stage, where a critical checkpoint eliminates meiotic cells with aberrant alignment of homologous chromosomes or/and DNA strand break (DSB) (Hunt & Hassold 2002). Based on the results from mice lacking meiotic components, the pachytene checkpoint is more rigorous in spermatogenesis than oogenesis. This difference might have caused a disruption of spermatogenesis in the organ culture. Recently, the comprehensive evaluation of culture conditions using meiosis- and haploid-specific reporter mice has made it possible to overcome this barrier. A novel culture method using agarose gel and Knockout Serum Replacement instead of fetal calf serum (FCS) produced functional spermatozoa harboring the haploid genome (Sato et al. 2011a). Moreover, eggs fertilized with the spermatozoa gave rise to healthy offspring, confirming that the culture system was successful at reconstituting spermatogenesis in the tests. The culture system is robust, as it succeeded in producing functional
sperm from the adult testis (Sato et al. 2015) as well as from frozen-thawed testicular tissues (Yokonishi et al. 2014). These studies suggest the possibility of applying the organ culture for the preservation of fertility.

Reconstitution of the male germ line: establishment of germline stem cells

Among the germ cell lineage, only SSCs meet the definition of stem cells, i.e., cells that can self-renew and differentiate simultaneously. For many years, the propagation of functional SSCs in culture has long been sought but remains elusive, even by enforced expression of T antigen or telomerase (Feng et al. 2002, van Pelt et al. 2002). A key finding in this regard was provided by the genetic analysis of glial cell-derived neurotrophic factor (GDNF), a critical factor for the self-renewal of SSCs. Transgenic mice overexpressing GDNF showed accumulation of undifferentiated spermatogonia in the testes (Meng et al. 2000). On the other hand, gene disruption of a Gdnf allele caused gradual decline of spermatogenesis and resulted in male infertility (Meng et al. 2000). Based on genetic studies and the careful evaluation of culture conditions, it was clearly demonstrated that functional SSCs could be propagated under a culture condition with GDNF as well as FGF2, EGF, LIF and a minimal volume (1%) of FCS (Kanatsu-Shinohara et al. 2003). The clusters of spermatogonia indefinitely maintained under these conditions were named germline stem cells (GSCs), and these cells can also differentiate into functional spermatoozoa upon transplantation into seminiferous tubules of the recipients (Fig. 3). The proliferation of these cells was GDNF dependent, reinforcing the notion that GSCs are a useful material to understand the mechanisms underlying self-renewal of SSCs. Indeed, genetic and biochemical analyses using GS cells suggested that transcription factors, such as Etv5, Bcl6, Oct4, Oct6, Taf4b and Foxo1 and signaling molecules, such as AKT, MEK and H-Ras, are crucial factors for self-renewal of SSCs (Kanatsu-Shinohara & Shinohara 2013). GSCs are also useful to provide genetic manipulation in the germ line. Transgenic and gene-disrupted mice were generated through GS cells (Nagano et al. 2001, Kanatsu-Shinohara et al. 2006). So far, the robust production of GSCs was successful in limited species of mice, rats and hamsters (Hamra et al. 2005, Ryu et al. 2005, Kanatsu-Shinohara et al. 2008). Identification of another factor(s) may be required for the development of a culture system that allows GSCs of other species to proliferate.

Combined with the organ culture system, the entire process of spermatogenesis can be reconstituted. GSCs transplanted into the seminiferous tubules of testes on the organ culture system gave rise to functional spermatoozoa (Fig. 3) (Sato et al. 2011b). This demonstrates that self-renewing GSCs can differentiate into functional spermatoozoa in culture. This technology may be useful for real-time observation of how GSCs settle in the niche and differentiate into spermatoozoa. Since the differentiation of GSCs in culture is limited, the combined organ culture system is currently the only path through which GSCs complete meiosis and spermiogenesis (Fig. 3).

Reconstitution of the male germ line: derivation of GSCs from mouse ESCs/iPSCs

Given that GSCs are derived from ESCs/iPSCs, mature sperm could be derived from pluripotent stem cells in combination with the organ culture system. Recently, Ishikura and coworkers reported the successful derivation of GSCs from mouse ESCs (Fig. 3) (Ishikura et al. 2016). In their study, PGCLCs derived from male ESCs were aggregated with somatic cells dissociated from male E12.5 gonads, which eventually reformed seminiferous tubular structures incorporated with...
PGCLCs. In the reconstituted tubules, PGCLCs differentiated into spermatogonia expressing PLZF. PGCLC-derived spermatogonia were then cultured under a condition for GSCs, which resulted in the successful derivations of several lines of GSC-like cells (GSCLCs) with the capability for infinite proliferation. The GSCLCs expressed representative marker genes, such as Plzf, Id4 and Gfra1, at levels comparable to those in bona fide GSCs. These GSCLCs were apparently functional, as they differentiated into mature sperm in the transplanted testes, and the resultant sperm were capable of fertilization and full-term development. However, it was also found that the efficiency of spermatogenesis completion varied among the GSCLC lines: in some lines spermatogenesis was frequently compromised in the transplanted testes. In these cases, the defective spermatogenesis might have been due to aberrant CpG methylation at the regulatory elements important for spermatogenesis (Ishikura et al. 2016). This is consistent with a report in which embryonic GSCs derived from fetal prospermatogonia exhibited aberrant CpG methylation that was inheritable by the subsequent generations (Lee et al. 2009). Since dynamic epigenetic alteration is accomplished at the fetal stage, prospermatogonia may be sensitive to manipulation in culture.

Reconstitution of the male germ line: direct derivation of haploid cells from male ESCs/iPSCs

Several reports have shown that haploid cells can be derived directly from mouse ESCs/iPSCs in culture (Fig. 3). Most of the culture strategy relies on spontaneous differentiation with some factors such as retinoic acid (RA). Geijsen and coworkers reported a culture system that produced haploid cells from ESCs through embryoid bodies (Geijsen et al. 2004). The haploid cells could be incorporated into eggs by intracytoplasmic injection, but the functionality of the zygotes has not been tested. Nayernia and coworkers further developed a culture system that produced haploid cells from ESCs that seemingly had the potential to give rise to offspring (Nayernia et al. 2006). However, the resultant offspring were apparently not healthy, as they were either smaller or larger than controls and showed premature death between 5 days and 5 months after birth. Recently, Zhou and coworkers reported a more robust system, in which haploid round spermatids could be derived from mouse ESCs (Zhou et al. 2016). In this culture system, which was based on those in the previous reports (Hayashi et al. 2011, 2012), PGCLCs were derived from ESCs and then cultured with W/Wv germ cell-deficient testicular cells. In a culture with combined media (with RA, BMP2/4/7 and activin A from 0 to 6 days of culture and with testosterone, FSH and bovine pituitary extract from 7 to 14 days of culture), round spermatids emerged within 2 weeks. The round spermatids possessed similar patterns of gene expression and of epigenetic states in the imprinting loci to spermatids in vivo. The resultant spermatids were injected into wild-type eggs, and the zygotes gave rise to offspring.

The sequence of technological developments leads us to believe that the production of male gametes, or at least haploid cells, from mouse ESCs in culture may be feasible. However, it is premature to reach a conclusion in this regard, since both the experimental and biological reproducibility remain to be evaluated. Since some culture technologies include complicated processes that sometimes yield different results, it is of particular importance to reproduce the experimental procedure with detailed protocols provided by the authors. It is also a concern that the differentiation process is accelerated in all the culture systems. It usually takes about 6 weeks to differentiate mature sperm from PGCs via prospermatogonia in vivo, whereas it requires only 2–3 weeks to progress from PGCLCs to haploid spermatid in culture (Zhou et al. 2016), and thus, the latter process is unlikely to recapitulate faithfully gametogenesis in vivo. Similarity between in vivo and in vitro gametogenesis or so-called ‘biological reproducibility’, seems particularly important, as evidence shows that prospermatogonia undergo dynamic epigenetic rearrangement (Davis et al. 2000, Ueda et al. 2000, Ly et al. 2015) and are likely sensitive to manipulation in culture (Lee et al. 2009, Ishikura et al. 2016). Moreover, biological reproducibility is also an important criterion when evaluating whether a culture system can be used as a model that can replace experimental animals.

Similar to the results in the mouse model, several reports have demonstrated the production of haploid cells directly from human ESCs/iPSCs (Fig. 3). Although these culture systems successfully halved the genome in the cells, it is difficult to provide a definition for ensuring that the haploid cells are male gametes. Functionality and/or morphology would be criteria for the definition, but the functionality would have never been evaluated, unless fertility and developmental potential are tested, which is not feasible in humans. Also, no report has confirmed that these systems yield mature sperm with their characteristic morphology. As shown in the mouse model, the differentiation process in vitro was much faster than that in vivo: it took only 10–14 days in vitro, whereas it usually takes at least months in the embryo for PGCs to progress to (pro)spermatogonia and approximate 60 days in the testis for spermatogonia to become mature sperm in humans. This leads to a similar concern of epigenetic aberrance in the haploid cells. Whether the culture system produces functional haploid cells through a canonical differentiation process must be tested using, for example, non-human primates. Recent reports have shown that the manner of PGC specification is largely conserved between humans, monkeys and even pigs (Kobayashi et al. 2017), making these reasonable animals to consider when modeling the production of functional haploid cells in humans.
Brief summary of male infertility

Recent reports have estimated that almost 15% of couples are infertile worldwide (Inhorn & Patrizio 2015), with more than half of these cases being attributable to factors in the male partner. Male infertility is due to genetic abnormalities in 15–20% of cases, and most of these resulted in oligospermia or azoospermia. Male infertility has both congenital and acquired causes: the former are triggered by genetic disorders including chromosomal and single gene deficiency, the latter by environmental factors. It can also be categorized into three main groups depending on the causal organ/tissue: (I) organs/tissues outside of the reproductive organs (e.g., disorders of the hypothalamus and pituitary gland and related endocrine disorders), (II) accessory reproductive organs (e.g., disorders of the prostate gland and seminal vesicle and related ejaculatory disorders) and (III) reproductive organs. Moreover, in the testis, spermatogenesis involves the cooperative actions of multiple cellular types, including germ cells and somatic cells. Therefore, the causes of male infertility can be further divided into either germ cell or somatic cell defects. Due to the focus of this review, we will focus on male infertility caused by germ cell defects. However, other more comprehensive reviews are available to overview the complexity of male infertility (Neto et al. 2016a,b, Craig et al. 2017, Krausz & Casamonti 2017).

One of the major types of genetic abnormalities that have been well defined as a cause of male sterility are the chromosomal abnormalities, such as XXY Klinefelter syndrome, Y chromosome microdeletions and XY, X mixed gonadal dysgenesis. XXY individuals have an additional X chromosome caused by nondisjunction of homologous recombination at meiosis (Hansmann 1979). Although the detailed mechanisms triggering germ cell loss remain elusive, XXY Klinefelter syndrome has been associated with early and progressive loss of germ cells in the testes (Ferguson-Smith 1959, Mroz et al. 1999). In terms of Y chromosome microdeletions, the azoospermia factor (AZF) region was mapped in 1996 (Vogt et al. 1996). The mapping revealed that AZF consists of 3 distinct regions, ‘a’, ‘b’ and ‘c’, which contain 3, 11 and 7 protein-coding genes, respectively (5 genes are overlapped in b and c regions). Either of these mutations is found in around 10% of azoospermic patients and 3% of infertile patients with severely reduced sperm counts (Reijo et al. 1995, Vogt et al. 1996, Yu et al. 2015). Apart from defects related to the chromosomal disorders, it is proposed that single gene mutations may also cause male infertility: comparative analyses indicate a number of genes shown in Table 1. Although the mutations and variants were observed in the loci, it is impossible to experimentally define the causal relationship to the genes in humans, unless the gene function is rescued in the patient. In vitro gametogenesis may be an option to evaluate the gene function on male gametogenesis (see below).

In recent years, lifestyle factors, and particularly metabolic state, have attracted attention as potential causes of male fertility. Thus, aspects of metabolic syndrome such as obesity and diabetes have been reported to decrease male fertility. However, the mechanisms underlying these associations are not well understood. In the testis, Sertoli cells, which provide nutrition to germ cells, preferentially import glucose and export lactate. Although the biological meaning of this lactate preference is not clear, developing germ cells have been shown to utilize lactate and thereby to induce anti-apoptotic effects (Erkkila et al. 2002). Some metabolites are tightly related to epigenetic regulation. For example, alpha-ketoglutaric acid (aKG) has co-enzymatic activity for the Jmjd family of histone demethylases and TET-mediated CpG hydroxymethylation (Losman & Kaelin 2013). S-Adenosyl methionine is a substrate of histone-to-protamine transition at spermiogenesis. It is also known that metabolic phenotypes are transduced beyond generations through possibly epigenetic modifications. Therefore, understanding the relation between metabolites and epigenetics in spermatogenesis is of particular importance.

Male infertility is induced by gonadotoxic treatments, which are typically chemotherap y and/or radiotherapy for cancer (Meistrich 2013). Since these treatments preferentially affect dividing cells, the spermatogenic pool is damaged in the testes. Indeed, a large proportion of cancer survivors suffer from azoospermia and oligospermia (Howell & Shalet 2005). In addition, toxicities induce chromosomal abnormalities, which are also a serious concern in spermatogenesis. At the present time, although semen cryopreservation is recommended in such cases, it is only applied for post-pubertal patients. Although preservation of testicular tissue and/or SSCs is a kind of solution, it could not exclude the risk for re-introduction of cancer cells. To overcome these problems, GSCs and an organ culture system would be an option (Fig. 4) (see below).

Perspectives on contribution of in vitro gametogenesis to male infertility

How in vitro gametogenesis could contribute to a cure for male infertility is a complex issue (Fig. 4). Needless to say, it is premature, from both an ethical and a technical point of view, to allow attempts to create individuals from haploid cells derived from human ESCs/iPSCs. What about organ culture? In the case of mice, sperm can be produced in an organ culture system. Given that this system is applicable to humans, it could be useful for sperm production from patients with infertility caused by cancer therapy and/or some genetic disorders. As described
Comprehensive analysis of genes that may cause infertility in humans and mice.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Chr.</th>
<th>Feature</th>
<th>Reference</th>
<th>Mouse KO phenotype (fertility in male)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>CATSPR1</td>
<td>11</td>
<td>Cation channel</td>
<td>Avenarius et al. (2009)</td>
<td>Defects in sperm motility and fertilization (infertile)</td>
<td>Ren et al. (2001)</td>
</tr>
<tr>
<td>CATSPR2</td>
<td>15</td>
<td>Cation channel</td>
<td>Avidan et al. (2003)</td>
<td>Failure to acquire hyperactivated motility (infertile)</td>
<td>Quill et al. (2003)</td>
</tr>
<tr>
<td>CREM</td>
<td>10</td>
<td>Transcription factor</td>
<td>Krausz &amp; Sassone-Corsi (2005)</td>
<td>Spermatids fail to differentiate into sperm (infertile)</td>
<td>Blendy et al. (1996)</td>
</tr>
<tr>
<td>DAZL</td>
<td>3</td>
<td>RNA-binding protein</td>
<td>Tung et al. (2006)</td>
<td>Almost complete absence of germ cells beyond the spermatogonia (infertile)</td>
<td>Ruggiu et al. (1997)</td>
</tr>
<tr>
<td>DNMT3L</td>
<td>21</td>
<td>Similarity to DNA methyltransferases</td>
<td>Stouffs et al. (2011)</td>
<td>Arrested and died around the early meiotic stage (infertile)</td>
<td>Bourc'his &amp; Bestor (2004)</td>
</tr>
<tr>
<td>KITLG</td>
<td>12</td>
<td>Ligand of the tyrosine-kinase receptor</td>
<td>Galan et al. (2006)</td>
<td>Fails to continue spermatogonial differentiation (infertile)</td>
<td>Brannan et al. (1992)</td>
</tr>
<tr>
<td>MCM8</td>
<td>20</td>
<td>Minichromosome maintenance proteins</td>
<td>Tenenbaum-Rakover et al. (2015)</td>
<td>Spermatocytes are blocked in meiotic prophase I (infertile)</td>
<td>Lutzmann et al. (2012)</td>
</tr>
<tr>
<td>NANO52</td>
<td>19</td>
<td>CCHC-type zinc finger protein</td>
<td>Kusz et al. (2009b)</td>
<td>Complete loss of spermatogonia (infertile)</td>
<td>Tsuda et al. (2003)</td>
</tr>
<tr>
<td>PICK1</td>
<td>22</td>
<td>Adaptor protein</td>
<td>Liu et al. (2010)</td>
<td>Disrupting acrosome formation (infertile)</td>
<td>Xiao et al. (2009)</td>
</tr>
<tr>
<td>SOHLH1</td>
<td>9</td>
<td>Transcription factor</td>
<td>Choi et al. (2010)</td>
<td>Spermatogonia does not differentiate properly (infertile)</td>
<td>Suzuki et al. (2012)</td>
</tr>
<tr>
<td>SYCE1</td>
<td>10</td>
<td>Synaptosomal complex</td>
<td>Maor-Sagie et al. (2015)</td>
<td>Synaptosomal complex do not assembled (infertile)</td>
<td>Bolcen-Filas et al. (2009)</td>
</tr>
<tr>
<td>SYCP3</td>
<td>12</td>
<td>Synaptosomal complex</td>
<td>Miyamoto et al. (2003)</td>
<td>Massive apoptotic cell death during meiotic prophase (infertile)</td>
<td>Yuan et al. (2000)</td>
</tr>
<tr>
<td>TAF4B</td>
<td>18</td>
<td>TATA-box-binding protein associated factor</td>
<td>Ayhan et al. (2014)</td>
<td>Gonocyte proliferation is impaired (gradually infertile)</td>
<td>Falender et al. (2005)</td>
</tr>
<tr>
<td>TEX11</td>
<td>X</td>
<td>Contains TRP protein-protein interaction domain</td>
<td>Yatsenko et al. (2015)</td>
<td>Spermatocytes apoptosis at pachytene (infertile)</td>
<td>Yang et al. (2008b)</td>
</tr>
<tr>
<td>TEX15</td>
<td>8</td>
<td>Serine-rich protein with no known function motifs</td>
<td>Okutman et al. (2015)</td>
<td>Spermatocytes exhibit a failure in chromosomal synapsis (infertile)</td>
<td>Yang et al. (2008a)</td>
</tr>
<tr>
<td>ZMYND15</td>
<td>17</td>
<td>MYND-containing zinc-binding protein</td>
<td>Ayhan et al. (2014)</td>
<td>Depletion of late spermatids (infertile)</td>
<td>Yan et al. (2010)</td>
</tr>
<tr>
<td>ZNF230</td>
<td>19</td>
<td>Zinc finger protein</td>
<td>Dong et al. (2005)</td>
<td>No obvious impairment (fertile)</td>
<td>Liu et al. (2014)</td>
</tr>
</tbody>
</table>
From a purely technological point of view, gene editing may be an option to cure infertility caused by single gene mutations (Fig. 4). Genome editing systems, such as zinc finger nucleases, TALENs and CRISPR-Cas9, have been rapidly developed over the last decade, making it feasible to edit the genome efficiently. By using GSCs, and correcting the gene mutation, followed by selection of a GSC clone with the correction (Chapman et al. 2015, Wu et al. 2015), it would theoretically be possible to get rid of any kind of gene mutation(s). Naturally, application of these genome editing techniques to the human germ line will necessitate a social debate on technological safety and bioethics. A part of the concern is that the genome editing systems sometimes have off-target effects that could cause an alternative gene mutation. This possibility could be excluded by using GSCs, since the entire genomic sequence can be checked in order to choose the desired GSC clones for propagation and use. Genetic and epigenetic stability would also become critical factors, once GSCs were established in humans. It has been reported that the genetic and epigenetic states in GSCs in mice are relatively stable (Kanatsu-Shinohara et al. 2005), reinforcing the notion that GSCs might one day be a strategy for male infertility. In addition to the genome editing, it may be feasible to eliminate excess chromosomes, such as one of the X chromosomes in XXY, from the GSCs spontaneously (Hirota et al. 2017) or by using a Cre-mediated recombination system (Matsumura et al. 2007).

At the present time, it seems more promising to use in vitro gametogenesis as a model system rather than an alternative source of gametes. First, an organ culture system would provide a platform that allows continuous observation of spermatogenesis. Since spermatogenesis includes various complicated processes, including meiosis and spermiogenesis, this platform would provide a better understanding of spermatogenesis. A culture device suitable for long-term culture with a live-imaging system has recently been under development (Komeya et al. 2016). A robust organ culture system would have a range of important applications for male infertility, such as the identification of key nutrients and their metabolic pathways, the screening of drugs that could cure male infertility or the testing of possible irritants that could disturb spermatogenesis. Because the genomes of GSCs can be manipulated, a functional assay for genes of interest by forced expression and/or knockout would be a powerful tool to identify genes critical for spermatogenesis (Fig. 4). Such an assay would be even more powerful if patient-specific GSCs could be routinely established. Then, causal relationships between gene mutations and symptoms would be easier to establish at the experimental level. Because the transplantation of GSCs also makes it possible to distinguish germ cell-intrinsic effects from somatic environmental effects, experiments combining both techniques—i.e., gene editing in GSCs followed by transplantation into allogeneic seminiferous tubules—may be particularly effective in cases in which the mutation is in a gene encoding a somatic factor and/or soluble factor, because such defects can be compensated by simply adding the recombinant protein to the medium (Fig. 4). The strategy may also be useful for male infertility with acquired causes—e.g., environmental factors, such as nutrition and metabolites, that cause infertility can be controlled in culture, which may overcome the defect in spermatogenesis. Since immunorejection may be ignored in an organ culture system, it is feasible to insert spermatogonia into allogeneic seminiferous tubules. This would be effective for infertility caused by defects in somatic cells and/or environmental factors.

earlier, the autotransplantation of testicular tissue and/or SSCs into the testes after cancer treatment is an option to preserve the fertility of cancer patients. This process may be disturbed by inefficient transplantation resulting in few cells with reconstitution of spermatogenesis—and/or by contamination of cancer cells causing recurrence of the disease. Organ culture of the testicular tissue would be an option to obviate these risks (Fig. 4). This possibility seems promising, since in mice, it is known that functional sperm can be obtained from frozen-thawed testicular tissues by an organ culture system (Yokonishi et al. 2014).

In the case of genetic disorders, one possible treatment strategy has been proposed based on experimental evidence. Namely, Sato and coworkers succeeded in restoring spermatogenesis in SLI/SII mutant testes bearing mutations in genes encoding SCF by culturing with recombinant SCF (Sato et al. 2012). This strategy would be particularly effective in cases in which the mutation is in a gene encoding a somatic factor and/or soluble factor, because such defects can be compensated by simply adding the recombinant protein to the medium (Fig. 4). The strategy may also be useful for male infertility with acquired causes—e.g., environmental factors, such as nutrition and metabolites, that cause infertility can be controlled in culture, which may overcome the defect in spermatogenesis. Since immunorejection may be ignored in an organ culture system, it is feasible to insert spermatogonia into allogeneic seminiferous tubules. This would be effective for infertility caused by defects in somatic cells and/or environmental factors.

earlier, the autotransplantation of testicular tissue and/or SSCs into the testes after cancer treatment is an option to preserve the fertility of cancer patients. This process may be disturbed by inefficient transplantation resulting in few cells with reconstitution of spermatogenesis—and/or by contamination of cancer cells causing recurrence of the disease. Organ culture of the testicular tissue would be an option to obviate these risks (Fig. 4). This possibility seems promising, since in mice, it is known that functional sperm can be obtained from frozen-thawed testicular tissues by an organ culture system (Yokonishi et al. 2014).

In the case of genetic disorders, one possible treatment strategy has been proposed based on experimental evidence. Namely, Sato and coworkers succeeded in restoring spermatogenesis in SLI/SII mutant testes bearing mutations in genes encoding SCF by culturing with recombinant SCF (Sato et al. 2012). This strategy would be particularly effective in cases in which the mutation is in a gene encoding a somatic factor and/or soluble factor, because such defects can be compensated by simply adding the recombinant protein to the medium (Fig. 4). The strategy may also be useful for male infertility with acquired causes—e.g., environmental factors, such as nutrition and metabolites, that cause infertility can be controlled in culture, which may overcome the defect in spermatogenesis. Since immunorejection may be ignored in an organ culture system, it is feasible to insert spermatogonia into allogeneic seminiferous tubules. This would be effective for infertility caused by defects in somatic cells and/or environmental factors.
by transplantation into testes in culture—would be an efficient approach for elucidating the detailed functions of genes. Taking these facts together, it is expected that in vitro methods will accelerate our understanding of spermatogenesis and male fertility.

Concluding remarks

In vitro gametogenesis using an organ culture system, ESCs, iPSCs or GSCs, can provide functional gametes in mice. These technologies can be beneficial in two different ways, either as an alternative source of gametes or as a model system that recapitulates gametogenesis in vivo. The quality of the gametes produced in vitro is the critical outcome. Recent experiments in mice have clearly shown that the quality of the gametes in vitro is inferior to that of the gametes in vivo, due, at least in part, to aberrant differentiation processes under suboptimal culture conditions. Further refinement of the culture conditions can thus be expected to increase the utility of in vitro gametogenesis. Reproductive biology and in vitro gametogenesis are most advanced in mice, and it will not be easy to generalize the murine gametogenesis method to humans and other animals. In particular, germ cell development requires the shortest length of time in mice. Because of this problem, together with the above-mentioned issues with quality, the study of in vitro gametogenesis has only just begun and constant efforts will be required for development of the technology.

Declaration of interests

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This study was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (KAKENHI #25114006) by the Uehara Memorial Foundation and by the Takeda Science Foundation.

Acknowledgement

The authors thank M Shono for reading of the manuscript and comments for helpful feedback. The authors apologize to colleagues whose work could not be cited owing to length limitations.

References


Blundell JA, Kaestner KH, Weinbauer GF, Nieschlag E & Schutz G 1996 Severe impairment of spermatogenesis in mice lacking the CREM gene. Nature 380 162–165. (https://doi.org/10.1038/380162a0)


Champy C 1920 Quelques résultats de la méthode de culture des tissues. Archives de Zoologie Expérimentale et Générale 60 461–500.


Gametogenesis in a culture dish


Gametogenesis in a culture dish


Received 31 August 2017
First decision 28 September 2017
Revised manuscript received 24 October 2017
Accepted 13 November 2017

www.reproduction-online.org
Reproduction (2017) 154 F79–F91